0001562180-17-001431.txt : 20170404
0001562180-17-001431.hdr.sgml : 20170404
20170404160141
ACCESSION NUMBER: 0001562180-17-001431
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170403
FILED AS OF DATE: 20170404
DATE AS OF CHANGE: 20170404
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Akebia Therapeutics, Inc.
CENTRAL INDEX KEY: 0001517022
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 208756903
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 245 FIRST STREET
STREET 2: SUITE 1100
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-871-2098
MAIL ADDRESS:
STREET 1: 245 FIRST STREET
STREET 2: SUITE 1100
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Dahan Michel
CENTRAL INDEX KEY: 0001669737
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36352
FILM NUMBER: 17738046
MAIL ADDRESS:
STREET 1: C/O AKEBIA THERAPEUTICS, INC.
STREET 2: 245 FIRST STREET, SUITE 1100
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
4
1
primarydocument.xml
PRIMARY DOCUMENT
X0306
4
2017-04-03
false
0001517022
Akebia Therapeutics, Inc.
AKBA
0001669737
Dahan Michel
C/O AKEBIA THERAPEUTICS, INC.
245 FIRST STREET
CAMBRIDGE
MA
02142
false
true
false
false
SVP, Chief Business Officer
Common Stock
2017-04-03
4
S
false
1401.00
9.1775
D
108623.00
D
Shares sold by reporting person to pay taxes in connection with the vesting of restricted stock pursuant to a December 23, 2013 award. Twenty-five percent of the shares vested on December 2, 2014, and the remaining shares vest in equal quarterly installments through October 1, 2017.
The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.15 to $9.24, inclusive. The reporting person undertakes to provide Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
Nicole R. Hadas, attorney-in-fact for Michel Dahan
2017-04-04